T-PLL
MCID: TCL005
MIFTS: 52

T-Cell Prolymphocytic Leukemia (T-PLL) malady

Categories: Cancer diseases, Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for T-Cell Prolymphocytic Leukemia

Aliases & Descriptions for T-Cell Prolymphocytic Leukemia:

Name: T-Cell Prolymphocytic Leukemia 56 29 69
T-Cell Chronic Lymphocytic Leukemia 56
Lymphocytic Leukemia T-Cell Chronic 52
Leukemia, T-Cell, Chronic 69
T-Pll 56

Characteristics:

Orphanet epidemiological data:

56
t-cell prolymphocytic leukemia
Age of onset: Adult;

Classifications:



External Ids:

Orphanet 56 ORPHA86871
MESH via Orphanet 43 D015461
UMLS via Orphanet 70 C2363142
ICD10 via Orphanet 34 C91.6
ICD10 33 C91.6

Summaries for T-Cell Prolymphocytic Leukemia

MalaCards based summary : T-Cell Prolymphocytic Leukemia, also known as t-cell chronic lymphocytic leukemia, is related to prolymphocytic leukemia and leukemia. An important gene associated with T-Cell Prolymphocytic Leukemia is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are ERK Signaling and IL-2 Pathway. The drugs Carboplatin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Wikipedia : 71 T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and... more...

Related Diseases for T-Cell Prolymphocytic Leukemia

Diseases in the B Cell Prolymphocytic Leukemia family:

T-Cell Prolymphocytic Leukemia

Diseases related to T-Cell Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 40)
id Related Disease Score Top Affiliating Genes
1 prolymphocytic leukemia 11.7
2 leukemia 10.9
3 lymphoma 10.3
4 lymphatic system disease 10.1 SMARCB1 VEGFA
5 bronchogenic cyst 10.1 ATM CHEK2
6 seminal vesicle chronic gonorrhea 10.1 ATM MTCP1 MYC TCL1A
7 kaposi sarcoma 10.0
8 t-cell leukemia 10.0
9 b-cell lymphomas 10.0
10 chronic lymphocytic leukemia 10.0
11 large granular lymphocyte leukemia 10.0
12 diffuse large b-cell lymphoma 10.0
13 t-cell large granular lymphocyte leukemia 10.0
14 sarcoma 10.0
15 bronchiectasis oligospermia 10.0 ATM CHEK2
16 pleoconial myopathy with salt craving 10.0 CD7 MS4A1
17 bifid uvula 10.0 ABL1 MYC TCL1A
18 marantic endocarditis 10.0 ATM MS4A1 MYC TCL1A
19 familial glucocorticoid deficiency 10.0 ATM CHEK2 VEGFA
20 bladder disease 9.9 CDKN1B MS4A1 MYC TCL1A
21 thoracic outlet syndrome 9.9 CDKN1B MYC SMARCB1
22 prostate cancer 9.9
23 anterior scleritis 9.9
24 breast cancer 9.9
25 prostatitis 9.9
26 purpura 9.9
27 nijmegen breakage syndrome 9.9
28 retinitis 9.9
29 ataxia-telangiectasia 9.9
30 acute liver failure 9.9
31 thyroiditis 9.9
32 vasculitis 9.9
33 ataxia 9.9
34 endotheliitis 9.9
35 panuveitis 9.9
36 myocardial infarction 9.9
37 scleritis 9.9
38 pulmonary fibrosis, idiopathic 9.7 ATM CD52 CDKN1B MS4A1 MYC TCL1A
39 chronic venous leg ulcers 9.7 ATM CD52 CDKN1B MS4A1 MYC TCL1A
40 macrostomia-preauricular tags-external ophthalmoplegia syndrome 8.0 ABL1 ATM BRCC3 CD52 CD7 CDKN1B

Graphical network of the top 20 diseases related to T-Cell Prolymphocytic Leukemia:



Diseases related to T-Cell Prolymphocytic Leukemia

Symptoms & Phenotypes for T-Cell Prolymphocytic Leukemia

GenomeRNAi Phenotypes related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.3 ABL1 SMARCB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.3 ABL1 ATM JAK3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.3 ATM SMARCB1 JAK3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.3 CHEK2 ATM
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.3 CHEK2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.3 ATM SMARCB1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.3 ABL1 CHEK2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.3 ATM JAK3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.3 ATM ABL1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.3 ABL1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.3 ATM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.3 ATM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.3 SMARCB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.3 SMARCB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.3 CHEK2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.3 ATM
17 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.3 ATM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.3 ABL1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.3 ABL1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.3 ATM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.3 ABL1 JAK3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.3 ABL1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-6 10.3 JAK3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.3 ATM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.3 ATM
26 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.3 ABL1 SMARCB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.3 ABL1 CHEK2 ATM SMARCB1 JAK3
28 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.3 JAK3
29 Decreased viability GR00221-A-1 10.23 ABL1 SMARCB1 MYC
30 Decreased viability GR00221-A-2 10.23 CHEK2 ABL1 SMARCB1
31 Decreased viability GR00221-A-3 10.23 ABL1 CHEK2 ATM JAK3 SMARCB1 MYC
32 Decreased viability GR00221-A-4 10.23 CHEK2 ATM
33 Decreased viability GR00342-S-1 10.23 ABL1
34 Decreased viability GR00342-S-2 10.23 ABL1 CHEK2
35 Decreased viability GR00342-S-3 10.23 ABL1
36 Decreased viability GR00381-A-1 10.23 SMARCB1
37 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.72 ABL1 CHEK2 ATM JAK1 JAK3
38 Decreased Hepatitis C Virus pseudoparticles (HCVpp GR00234-A-1 9.54 CDKN1B ATM JAK1
39 Decreased viability in HMC1.1 cells GR00105-A-0 9.16 JAK1 JAK3
40 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.1 ABL1 BRCC3 CDKN1B CHEK2 ATM NFKB1

MGI Mouse Phenotypes related to T-Cell Prolymphocytic Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 MS4A1 ATM MYC CD7 CDKN1B NFKB1
2 endocrine/exocrine gland MP:0005379 10.02 ABL1 JAK3 ATM MYC CD7 CDKN1B
3 immune system MP:0005387 9.93 MS4A1 ATM MYC CD7 CDKN1B NFKB1
4 digestive/alimentary MP:0005381 9.91 JAK3 ABL1 MYC CDKN1B NFKB1 SMARCB1
5 craniofacial MP:0005382 9.88 ABL1 MYC NFKB1 CDKN1B JAK1 VEGFA
6 liver/biliary system MP:0005370 9.5 ABL1 MYC CDKN1B NFKB1 SMARCB1 JAK1
7 neoplasm MP:0002006 9.1 ATM MYC CDKN1B CHEK2 SMARCB1 VEGFA

Drugs & Therapeutics for T-Cell Prolymphocytic Leukemia

Drugs for T-Cell Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 249)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
2
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
3
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
4
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
5
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
6
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1 55-98-1 2478
7
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
8
Ofloxacin Approved Phase 3 82419-36-1 4583
9
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
10
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
11
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
12
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
13
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
14
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
15
Morphine Approved, Investigational Phase 3 57-27-2 5288826
16
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
17
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
18
Ondansetron Approved Phase 3 99614-02-5 4595
19
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
20
Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
22
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
23
Dalteparin Approved Phase 3 9041-08-1
24
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
25
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
26
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
27
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
28
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
29
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
30 Analgesics Phase 3,Phase 2
31 Alkylating Agents Phase 2, Phase 3,Phase 1
32 Neurotransmitter Agents Phase 3
33 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
34 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2
35 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
36 Dermatologic Agents Phase 3,Phase 2,Phase 1
37 Anesthetics Phase 3
38 Anesthetics, Dissociative Phase 3
39 Anesthetics, General Phase 3
40 Anesthetics, Intravenous Phase 3
41 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
43 Excitatory Amino Acid Antagonists Phase 3
44 Excitatory Amino Acids Phase 3
45 Anti-Infective Agents Phase 3,Phase 2,Phase 1
46 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
47 Antilymphocyte Serum Phase 2, Phase 3,Phase 1
48 Antimetabolites Phase 3,Phase 2,Phase 1
49 Renal Agents Phase 3,Phase 1,Phase 2
50 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 130)
id Name Status NCT ID Phase
1 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
3 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
4 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
5 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
6 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
7 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
8 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
9 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
10 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
12 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
13 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
14 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Active, not recruiting NCT01231412 Phase 3
15 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
16 Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) Completed NCT01186640 Phase 2
17 Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Completed NCT00278213 Phase 2
18 Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL Completed NCT00452374 Phase 1, Phase 2
19 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2
20 Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Completed NCT00053196 Phase 2
21 Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant Completed NCT01244906 Phase 2
22 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2
23 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
24 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
25 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2
26 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2
27 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2
28 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
29 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2
30 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2
31 Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer Completed NCT00782379 Phase 2
32 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Completed NCT00448201 Phase 2
33 Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases Completed NCT00453206 Phase 2
34 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting NCT01251575 Phase 2
35 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Recruiting NCT02742727 Phase 1, Phase 2
36 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT01008462 Phase 2
37 CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Recruiting NCT02819583 Phase 1, Phase 2
38 Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Recruiting NCT02851589 Phase 1, Phase 2
39 Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy Recruiting NCT01735604 Phase 1, Phase 2
40 Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Recruiting NCT02005289 Phase 2
41 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2
42 Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Recruiting NCT02988466 Phase 2
43 Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Active, not recruiting NCT02512497 Phase 1, Phase 2
44 Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Active, not recruiting NCT00005803 Phase 1, Phase 2
45 Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Active, not recruiting NCT00060424 Phase 2
46 Panobinostat Biological Correlates Study Active, not recruiting NCT01658241 Phase 2
47 Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment Active, not recruiting NCT00416351 Phase 1, Phase 2
48 Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT00104858 Phase 2
49 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Active, not recruiting NCT00089011 Phase 2
50 Fludarabine and PK-Directed Busulfan With or Without ATG Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases Active, not recruiting NCT00448357 Phase 1, Phase 2

Search NIH Clinical Center for T-Cell Prolymphocytic Leukemia

Genetic Tests for T-Cell Prolymphocytic Leukemia

Genetic tests related to T-Cell Prolymphocytic Leukemia:

id Genetic test Affiliating Genes
1 T-Cell Prolymphocytic Leukemia 29

Anatomical Context for T-Cell Prolymphocytic Leukemia

MalaCards organs/tissues related to T-Cell Prolymphocytic Leukemia:

39
T Cells, Bone Marrow, Skin, Spleen, Liver, Bone, Lymph Node

Publications for T-Cell Prolymphocytic Leukemia

Articles related to T-Cell Prolymphocytic Leukemia:

(show top 50) (show all 134)
id Title Authors Year
1
Linear nonpalpable purpura in a young male: a unique presentation of leukemia cutis in T-cell prolymphocytic leukemia. ( 28083939 )
2017
2
Small Cell Variant of T-Cell Prolymphocytic Leukemia with Acquired Palmoplantar Keratoderma and Cutaneous Infiltration. ( 26813734 )
2016
3
Intraocular T-cell Prolymphocytic Leukemia Masquerading as Necrotizing Herpetic Retinitis. ( 27736276 )
2016
4
Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia. ( 27504481 )
2016
5
Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation? ( 25712069 )
2015
6
T-cell chronic lymphocytic leukemia or small-cell variant of T-cell prolymphocytic leukemia: a historical perspective and search for consensus. ( 25846234 )
2015
7
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. ( 26109102 )
2015
8
A pediatric case of T-cell prolymphocytic leukemia. ( 25417638 )
2015
9
Encephalitozoon hellem in a patient with CD4(+) T-cell prolymphocytic leukemia: case report and genomic identification. ( 26299583 )
2015
10
T-cell prolymphocytic leukemia: survival improves with alemtuzemab, but stem cell transplant eligibility 'counts' even more. ( 26293613 )
2015
11
T-cell prolymphocytic leukemia presenting with leukemic serous effusion in a prostate cancer patient. ( 26881553 )
2015
12
T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis. ( 26106002 )
2015
13
Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL). ( 25888568 )
2015
14
A T-cell prolymphocytic leukemia case with central nervous system involvement. ( 26550397 )
2015
15
Expression of S100 Protein in CD4-positive T-cell Lymphomas Is Often Associated With T-cell Prolymphocytic Leukemia. ( 26379148 )
2015
16
Survival trends in T cell prolymphocytic leukemia: A SEER database analysis. ( 26292711 )
2015
17
Diffuse anterior scleritis and secondary glaucoma as a manifestation of adult T-cell prolymphocytic leukemia. ( 24977988 )
2014
18
T-cell prolymphocytic leukemia with extensive cardiovascular infiltrate leading to multiple myocardial infarctions and cardiac death. ( 25593528 )
2014
19
Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. ( 24446122 )
2014
20
T-cell Prolymphocytic Leukemia Frequently Shows Cutaneous Involvement and Is Associated With Gains of MYC, Loss of ATM, and TCL1A Rearrangement. ( 25310835 )
2014
21
Identification of a novel SEPT9-ABL1 fusion gene in a patient with T-cell prolymphocytic leukemia. ( 25068103 )
2014
22
Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. ( 24825865 )
2014
23
Infiltration of the thyroid gland by T-cell prolymphocytic leukemia. ( 24762052 )
2014
24
T-cell prolymphocytic leukemia in a 63-year-old female with a pre-existing T-cell large granular lymphocytic leukemia: Metachronous T-cell leukemias with discordant subset restrictions (CD4 versus CD8) and distinct clonal identities. ( 25238936 )
2014
25
Central nervous system involvement of T-cell prolymphocytic leukemia diagnosed with stereotactic brain biopsy: case report. ( 24764733 )
2014
26
Immunophenotypic characterization of T-cell prolymphocytic leukemia. ( 24124154 )
2013
27
[Splenic rupture associated with aggressive conversion of indolent T-cell prolymphocytic leukemia]. ( 23676644 )
2013
28
T-cell prolymphocytic leukemia (T-PLL) with overlapping cytomorphological features with T-CLL and T-ALL: a case initially diagnosed by fine-needle aspiration cytology and immunocytochemistry. ( 21987484 )
2013
29
Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. ( 24048415 )
2013
30
Coronary vasculitis associated with T-cell prolymphocytic leukemia. ( 23731632 )
2013
31
Cutaneous presentation of T-cell prolymphocytic leukemia. ( 23513557 )
2013
32
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. ( 23512246 )
2013
33
T-cell prolymphocytic leukemia. ( 23382603 )
2013
34
T-cell prolymphocytic leukemia in Japan: is it a variant? ( 22527853 )
2012
35
B- and T-cell prolymphocytic leukemia: antibody approaches. ( 23233647 )
2012
36
Cerebriform variant type of T cell prolymphocytic leukemia with complex karyotype including an additional segment at 1p36.1. ( 23054642 )
2012
37
TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients. ( 22189846 )
2012
38
Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia. ( 22980700 )
2012
39
Pediatric T-cell prolymphocytic leukemia with an isolated 12(p13) deletion and aberrant CD117 expression. ( 23211022 )
2012
40
T-cell prolymphocytic leukemia with cutaneous involvement as the presenting feature. ( 22615522 )
2012
41
A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia. ( 22517037 )
2012
42
A Comprehensive Update on Molecular and Cytogenetic Abnormalities in T-cell Prolymphocytic Leukemia (T-pll). ( 23183331 )
2012
43
Erythematous eruption with marked conjunctival injection--quiz case. Diagnosis: leukemia cutis with conjunctival involvement in the setting of T-cell prolymphocytic leukemia (T-PLL). ( 23069962 )
2012
44
"T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics: a multidisciplinary approach". ( 23211026 )
2012
45
Epstein-Barr virus-negative classical Hodgkin's lymphoma in a patient with T-cell prolymphocytic leukemia treated with fludarabine. ( 22706535 )
2012
46
Case Study Interpretation--Houston: Case 4. T-cell prolymphocytic leukemia. ( 21638771 )
2011
47
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. ( 21948296 )
2011
48
T-cell prolymphocytic leukemia presenting as red eye. ( 21572742 )
2011
49
A case of T cell prolymphocytic leukemia involving blast transformation. ( 21505955 )
2011
50
CD30-positive EBV-associated diffuse large B-cell lymphoma occurring after immunosuppressive therapy for T-cell prolymphocytic leukemia. ( 21454193 )
2011

Variations for T-Cell Prolymphocytic Leukemia

ClinVar genetic disease variations for T-Cell Prolymphocytic Leukemia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 ATM NM_000051.3(ATM): c.7271T> G (p.Val2424Gly) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs28904921 GRCh37 Chromosome 11, 108199929: 108199929
2 ATM NM_000051.3(ATM): c.5044G> C (p.Asp1682His) single nucleotide variant Pathogenic rs121434217 GRCh37 Chromosome 11, 108170479: 108170479
3 ATM NM_000051.3(ATM): c.5309C> G (p.Ser1770Ter) single nucleotide variant Pathogenic rs121434223 GRCh37 Chromosome 11, 108172506: 108172506

Copy number variations for T-Cell Prolymphocytic Leukemia from CNVD:

7 (show top 50) (show all 758)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14323 1 107060000 118270000 Deletion T-cell prolymphocytic leukemia
2 17205 1 141501392 142732360 Amplification T-cell prolymphocytic leukemia
3 19890 1 151880356 153088354 Deletion T-cell prolymphocytic leukemia
4 22015 1 164099958 164243756 Amplification T-cell prolymphocytic leukemia
5 24296 1 178292024 178520303 Amplification T-cell prolymphocytic leukemia
6 24451 1 180754716 183730500 Amplification T-cell prolymphocytic leukemia
7 25710 1 193462805 193618427 Deletion T-cell prolymphocytic leukemia
8 26226 1 198221297 245353397 Amplification T-cell prolymphocytic leukemia
9 29813 1 236310000 236970000 Deletion T-cell prolymphocytic leukemia
10 31149 1 25598247 25881984 Deletion T-cell prolymphocytic leukemia
11 31214 1 26102907 26624823 Deletion T-cell prolymphocytic leukemia
12 31215 1 26102907 26936965 Deletion T-cell prolymphocytic leukemia
13 31328 1 26860573 29239576 Deletion T-cell prolymphocytic leukemia
14 35233 1 6146230 6344245 Deletion T-cell prolymphocytic leukemia
15 35791 1 67452671 99313693 Deletion T-cell prolymphocytic leukemia
16 36896 1 825852 120863833 Amplification T-cell prolymphocytic leukemia
17 39073 10 108954534 111745117 Deletion T-cell prolymphocytic leukemia
18 39204 10 111824569 135311386 Amplification T-cell prolymphocytic leukemia
19 40780 10 133604797 135311386 Deletion T-cell prolymphocytic leukemia
20 41072 10 135165535 135311386 Amplification T-cell prolymphocytic leukemia
21 41217 10 148946 135311386 Amplification T-cell prolymphocytic leukemia
22 41219 10 148946 5692243 Deletion T-cell prolymphocytic leukemia
23 41413 10 17718148 22325377 Deletion T-cell prolymphocytic leukemia
24 41736 10 23032969 39064552 Deletion T-cell prolymphocytic leukemia
25 41964 10 26990000 30260000 Deletion T-cell prolymphocytic leukemia
26 42441 10 34110000 35980000 Deletion T-cell prolymphocytic leukemia
27 43355 10 46363383 47154881 Amplification T-cell prolymphocytic leukemia
28 44297 10 54778135 56318960 Deletion T-cell prolymphocytic leukemia
29 45076 10 67100000 71360000 Deletion T-cell prolymphocytic leukemia
30 46742 10 85720790 86922140 Deletion T-cell prolymphocytic leukemia
31 47214 10 90488702 94393578 Deletion T-cell prolymphocytic leukemia
32 48517 11 100045570 103051410 Deletion T-cell prolymphocytic leukemia
33 49138 11 10330000 11140000 Deletion T-cell prolymphocytic leukemia
34 49397 11 106417979 114849006 Deletion T-cell prolymphocytic leukemia
35 49494 11 107346114 107685623 Deletion T-cell prolymphocytic leukemia
36 49495 11 107346114 108015771 Deletion T-cell prolymphocytic leukemia
37 49502 11 107401046 107685623 Deletion T-cell prolymphocytic leukemia
38 49503 11 107419503 108193907 Deletion T-cell prolymphocytic leukemia
39 49515 11 107511257 108661992 Deletion T-cell prolymphocytic leukemia
40 49523 11 107598768 107745036 Deletion ATM T-cell prolymphocytic leukemia
41 49774 11 110891599 111596604 Deletion T-cell prolymphocytic leukemia
42 50371 11 117492601 119996648 Deletion T-cell prolymphocytic leukemia
43 50952 11 120493810 122186945 Deletion T-cell prolymphocytic leukemia
44 51031 11 122000000 131630000 Gain T-cell prolymphocytic leukemia
45 51124 11 123252803 123608170 Deletion T-cell prolymphocytic leukemia
46 51271 11 124529138 125115632 Deletion T-cell prolymphocytic leukemia
47 51421 11 125855565 126161131 Deletion T-cell prolymphocytic leukemia
48 51521 11 127437820 128227400 Deletion T-cell prolymphocytic leukemia
49 51526 11 127525578 128328976 Deletion T-cell prolymphocytic leukemia
50 51529 11 127550030 128131996 Deletion T-cell prolymphocytic leukemia

Expression for T-Cell Prolymphocytic Leukemia

Search GEO for disease gene expression data for T-Cell Prolymphocytic Leukemia.

Pathways for T-Cell Prolymphocytic Leukemia

Pathways related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 ABL1 ATM CDKN1B CHEK2 JAK1 JAK3
2
Show member pathways
13.17 ABL1 CDKN1B JAK1 JAK3 MYC NFKB1
3
Show member pathways
12.98 ATM CDKN1B JAK1 JAK3 MYC NFKB1
4
Show member pathways
12.89 ATM CHEK2 JAK1 JAK3 NFKB1
5
Show member pathways
12.76 CDKN1B JAK1 JAK3 MYC NFKB1
6 12.62 ABL1 CDKN1B JAK1 MYC NFKB1 VEGFA
7
Show member pathways
12.56 JAK1 JAK3 MYC NFKB1
8
Show member pathways
12.52 CDKN1B JAK1 MYC NFKB1
9 12.48 ATM BRCC3 CDKN1B CHEK2
10 12.45 ABL1 ATM CDKN1B MYC NFKB1 VEGFA
11
Show member pathways
12.4 CDKN1B JAK1 JAK3 MYC NFKB1
12
Show member pathways
12.38 JAK1 JAK3 NFKB1 VEGFA
13
Show member pathways
12.36 ABL1 ATM CDKN1B CHEK2 MYC
14 12.35 ABL1 ATM CDKN1B CHEK2 MYC
15
Show member pathways
12.34 ABL1 ATM BRCC3 CHEK2
16 12.29 ATM CHEK2 JAK1 JAK3 MYC NFKB1
17
Show member pathways
12.28 ABL1 CDKN1B JAK1 MYC NFKB1
18 12.27 CDKN1B JAK1 JAK3 NFKB1
19
Show member pathways
12.26 CDKN1B JAK1 JAK3 NFKB1 VEGFA
20 12.26 CDKN1B JAK1 JAK3 MYC NFKB1
21 12.21 ATM CDKN1B MYC NFKB1
22
Show member pathways
12.2 CDKN1B CHEK2 MYC NFKB1
23 12.17 JAK1 MYC NFKB1 VEGFA
24 12.09 CDKN1B JAK1 JAK3 MTCP1 MYC NFKB1
25 11.98 JAK1 JAK3 MYC VEGFA
26 11.88 CDKN1B NFKB1 VEGFA
27 11.88 CDKN1B NFKB1 VEGFA
28
Show member pathways
11.88 ABL1 CDKN1B JAK1 MYC NFKB1 VEGFA
29
Show member pathways
11.85 JAK1 JAK3 NFKB1
30 11.83 ABL1 ATM CDKN1B MYC NFKB1
31 11.82 ABL1 JAK1 JAK3
32 11.82 ABL1 CDKN1B MYC
33
Show member pathways
11.81 ABL1 ATM CHEK2
34 11.79 CDKN1B MYC NFKB1
35
Show member pathways
11.79 ATM CHEK2 SMARCB1
36 11.72 ATM CDKN1B MYC
37 11.68 CDKN1B JAK1 MYC
38 11.67 ATM CHEK2 MYC
39
Show member pathways
11.66 JAK1 JAK3 MYC NFKB1
40 11.61 ABL1 ATM CHEK2
41 11.59 ABL1 CDKN1B SMARCB1
43 11.54 ABL1 ATM CDKN1B MYC NFKB1
44 11.53 JAK1 MYC NFKB1 VEGFA
45 11.51 ABL1 ATM CDKN1B MYC
46 11.48 ATM CHEK2 NFKB1
47 11.46 CDKN1B MYC NFKB1 VEGFA
48
Show member pathways
11.44 JAK1 JAK3 VEGFA
49 11.4 ATM CHEK2 MYC NFKB1
50
Show member pathways
11.38 CDKN1B JAK1 JAK3 MYC

GO Terms for T-Cell Prolymphocytic Leukemia

Cellular components related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 8.8 ABL1 JAK1 JAK3

Biological processes related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.93 ATM BRCC3 CDKN1B CHEK2 SMARCB1
2 protein phosphorylation GO:0006468 9.92 ABL1 ATM CHEK2 JAK1 JAK3
3 phosphorylation GO:0016310 9.91 ABL1 ATM CDKN1B CHEK2 JAK1 JAK3
4 cellular response to DNA damage stimulus GO:0006974 9.88 ABL1 ATM BRCC3 CHEK2 MYC
5 protein autophosphorylation GO:0046777 9.71 ABL1 ATM CHEK2 JAK1
6 DNA repair GO:0006281 9.65 ABL1 ATM BRCC3 CHEK2 SMARCB1
7 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.63 ATM CDKN1B CHEK2
8 peptidyl-tyrosine autophosphorylation GO:0038083 9.54 ABL1 JAK1 JAK3
9 replicative senescence GO:0090399 9.51 ATM CHEK2
10 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.5 ABL1 ATM CHEK2
11 signal transduction in response to DNA damage GO:0042770 9.49 ABL1 CHEK2
12 ovarian follicle development GO:0001541 9.33 ATM MYC VEGFA
13 cell cycle arrest GO:0007050 9.26 ABL1 ATM CDKN1B MYC
14 DNA damage induced protein phosphorylation GO:0006975 8.8 ABL1 ATM CHEK2

Molecular functions related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.65 ABL1 ATM CHEK2 JAK1 JAK3
2 protein phosphatase binding GO:0019903 9.33 CDKN1B JAK1 JAK3
3 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.13 ABL1 JAK1 JAK3
4 kinase activity GO:0016301 9.1 ABL1 ATM CDKN1B CHEK2 JAK1 JAK3

Sources for T-Cell Prolymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....